Efficacy and safety of liposomal irinotecan combined with cadonilimab as second-line treatment for extensive-stage small cell lung cancer (ES-SCLC): A prospective, single arm phase II clinical study.

Authors: Xuquan Jing, Yaru Tian, Zhe Wang, Ning Tang, Guangjian Yang, Xiaomeng Liu, Haiyong Wang, Hui Zhu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20104

Source: Full article

e20104